Jean-Charles Soria

List of Publications by Year
in descending order

329 papers	50,317 citations	4370 86 h-index	1627 215 g-index
361 all docs	361 docs citations	361 times ranked	54604 citing authors

#	Article	IF	Citations
1	Pembrolizumab for the Treatment of Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 372, 2018-2028.	13.9	5,183
2	Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature, 2014, 515, 563-567.	13.7	4,342
3	Gut microbiome influences efficacy of PD-1â€“based immunotherapy against epithelial tumors. Science, 2018, 359, 91-97.	6.0	3,689
4	Osimertinib in UntreatedEGFR-Mutated Advanced Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 378, 113-125.	13.9	3,530
5	Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. New England Journal of Medicine, 2020, 382, 41-50.	13.9	1,725
6	DNA Repair by ERCC1 in Nonâ€“Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy. New England Journal of Medicine, 2006, 355, 983-991.	13.9	1,611
7	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics, 2012, 44, 1104-1110.	9.4	1,186
8	Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clinical Cancer Research, 2017, 23, 1920-1928.	3.2	960
9	First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet, The, 2017, 389, 917-929.	6.3	919
10	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nature Reviews Clinical Oncology, 2016, 13, 473-486.	12.5	831
11	A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncology, The, 2018, 19, 1180-1191.	5.1	811
12	Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet, The, 2016, 387, 1415-1426.	6.3	790
13	Management of non-small-cell lung cancer: recent developments. Lancet, The, 2013, 382, 709-719.	6.3	658
14	Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. Immunity, 2016, 45, 931-943.	6.6	645
15	Rociletinib in EGFR-Mutated Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 372, 1700-1709.	13.9	615
16	Hyperprogressive Disease in Patients With Advanced Nonâ€“Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. JAMA Oncology, 2018, 4, 1543.	3.4	567
17	High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discovery, 2017, 7, 586-595.	7.7	554
18	Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. OncoImmunology, 2016, 5, e1071008.	2.1	545

#	Article	IF	Citations
19	Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. JAMA Dermatology, 2016, 152, 45.	2.0	539
20	Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncology, The, 2005, 6, 491-500.	5.1	527
21	Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncology, The, 2018, 19, 649-659.	5.1	450
22	Dendritic cellâ€“derived exosomes for cancer therapy. Journal of Clinical Investigation, 2016, 126, 1224-1232.	3.9	427
23	Targeting FGFR Signaling in Cancer. Clinical Cancer Research, 2015, 21, 2684-2694.	3.2	399
24	Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncology, The, 2015, 16, 897-907.	5.1	389
25	Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nature Medicine, 2019, 25, 751-758.	15.2	362
26	Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncology, The, 2015, 16, 990-998.	5.1	353
27	ERCC1 Isoform Expression and DNA Repair in Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2013, 368, 1101-1110.	13.9	342
28	Optimizing oncolytic virotherapy in cancer treatment. Nature Reviews Drug Discovery, 2019, 18, 689-706.	21.5	325
29	Phase I Dose-Escalation Study of JNJ-42756493, an Oral Panâ€“Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2015, 33, 3401-3408.	0.8	324
30	Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clinical Cancer Research, 2002, 8, 1178-84.	3.2	312
31	Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Nonâ€“Small-Cell Lung Cancer. JAMA - Journal of the American Medical Association, 2004, 292, 470.	3.8	305
32	Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nature Reviews Clinical Oncology, 2018, 15, 748-762.	12.5	304
33	Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis. PLoS Medicine, 2016, 13, e1002201.	3.9	300
34	Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 1223-1230.	0.8	300
35	Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities. Clinical Cancer Research, 2012, 18, 2443-2451.	3.2	274
36	Pooled Analysis of the Prognostic and Predictive Effects of KRAS Mutation Status and KRAS Mutation Subtype in Early-Stage Resected Nonâ€“Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. Journal of Clinical Oncology, 2013, 31, 2173-2181.	0.8	270

#	Article	IF	Citations
37	The Evolving Role of Histology in the Management of Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 5311-5320.	0.8	247
38	Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection. Journal of Clinical Oncology, 2015, 33, 3439-3446.	0.8	234
39	Detection, Characterization, and Inhibition of FGFRâ€“TACC Fusions in IDH Wild-type Glioma. Clinical Cancer Research, 2015, 21, 3307-3317.	3.2	230
40	Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2011, 29, 4442-4451.	0.8	227
41	Tumor Mutation Burden as a Biomarker in Resected Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 2995-3006.	0.8	223
42	PARP inhibition enhances tumor cellâ€“intrinsic immunity in ERCC1-deficient nonâ€“small cell lung cancer. Journal of Clinical Investigation, 2019, 129, 1211-1228.	3.9	222
43	Antibodyâ€“Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index. Clinical Cancer Research, 2019, 25, 5441-5448.	3.2	217
44	Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 511-525.	1.4	212
45	Bevacizumab in Patients with Nonsquamous Nonâ€“Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study. Clinical Cancer Research, 2015, 21, 1896-1903.	3.2	199
46	Erlotinib for Frontline Treatment of Advanced Nonâ€“Small Cell Lung Cancer: a Phase II Study. Clinical Cancer Research, 2006, 12, 6049-6055.	3.2	197
47	A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal. PLoS Computational Biology, 2018, 14, e1005965.	1.5	191
48	Cyclooxygenase-2 as a target for anticancer drug development. Critical Reviews in Oncology/Hematology, 2006, 59, 51-64.	2.0	186
49	Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. Clinical Cancer Research, 2016, 22, 4309-4321.	3.2	182
50	Involvement of aquaporins in colorectal carcinogenesis. Oncogene, 2003, 22, 6699-6703.	2.6	175
51	Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nature Cancer, 2021, 2, 794-802.	5.7	173
52	Next-Generation Sequencing Reveals High Concordance of Recurrent Somatic Alterations Between Primary Tumor and Metastases From Patients With Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2013, 31, 2167-2172.	0.8	170
53	Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686). Clinical Cancer Research, 2016, 22, 2386-2395.	3.2	169
54	Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited. Cancer Discovery, 2021, 11, 233-236.	7.7	169

#	Article	IF	Citations
55	Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Research, 2019, 29, 846-861.	5.7	160
56	Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving Sorafenib. Journal of Clinical Oncology, 2009, 27, e59-e61.	0.8	152
57	Aquaporin 1 Is Overexpressed in Lung Cancer and Stimulates NIH-3T3 Cell Proliferation and Anchorage-Independent Growth. American Journal of Pathology, 2006, 168, 1345-1353.	1.9	150
58	Targeting the DNA damage response in immuno-oncology: developments and opportunities. Nature Reviews Cancer, 2021, 21, 701-717.	12.8	150
59	First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas. Clinical Cancer Research, 2017, 23, 908-917.	3.2	149
60	Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients. Cancer Research, 2011, 71, 661-665.	0.4	144
61	Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials. Clinical Cancer Research, 2014, 20, 246-252.	3.2	144
62	Cisplatin Resistance Associated with PARP Hyperactivation. Cancer Research, 2013, 73, 2271-2280.	0.4	143
63	Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1319-1327.	0.5	138
64	First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors. Clinical Cancer Research, 2012, 18, 4806-4819.	3.2	136
65	Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). European Journal of Cancer, 2017, 84, 212-218.	1.3	132
66	Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2012, 13, 391-395.	1.1	128
67	Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers. Clinical Cancer Research, 2016, 22, 5983-5991.	3.2	124
68	Excision Repair Cross Complementation Group 1 Immunohistochemical Expression Predicts Objective Response and Cancer-Specific Survival in Patients Treated by Cisplatin-Based Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2007, 13, 3855-3859.	3.2	122
69	Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities?. Journal of Clinical Oncology, 2011, 29, 1728-1735.	0.8	120
70	Skin Tumors Induced by Sorafenib; Paradoxic RASâ€“RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53, and TGFBR1. Clinical Cancer Research, 2012, 18, 263-272.	3.2	119
71	Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2013, 19, 1257-1268.	3.2	117
72	Nonapoptotic Role for Apaf-1 in the DNA Damage Checkpoint. Molecular Cell, 2007, 28, 624-637.	4.5	116

#	Article	IF	Citations
73	EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects. Cancer Treatment Reviews, 2012, 38, 416-430.	3.4	114
74	Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer. Clinical Cancer Research, 2020, 26, 242-255.	3.2	114
75	A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers. Clinical Cancer Research, 2017, 23, 5366-5373.	3.2	109
76	Cell Cycle Regulators and Outcome of Adjuvant Cisplatin-Based Chemotherapy in Completely Resected Nonâ€“Small-Cell Lung Cancer: The International Adjuvant Lung Cancer Trial Biologic Program. Journal of Clinical Oncology, 2007, 25, 2735-2740.	0.8	107
77	Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies. Cancer Discovery, 2021, 11, 874-899.	7.7	107
78	Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial. Clinical Cancer Research, 2016, 22, 2960-2968.	3.2	103
79	Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. Cancer Research, 2002, 62, 351-5.	0.4	103
80	Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial. Clinical Cancer Research, 2017, 23, 6101-6112.	3.2	102
81	Renal toxicities associated with pembrolizumab. CKJ: Clinical Kidney Journal, 2019, 12, 81-88.	1.4	101
82	Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort. Nature Cancer, 2020, 1, 965-975.	5.7	98
83	Differential Expression of Biomarkers in Primary Non-small Cell Lung Cancer and Metastatic Sites. Journal of Thoracic Oncology, 2009, 4, 1212-1220.	0.5	97
84	Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nature Clinical Practice Oncology, 2008, 5, 268-278.	4.3	96
85	The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nature Reviews Clinical Oncology, 2012, 9, 144-155.	12.5	96
86	Long-Term Survival in Patients Responding to Antiâ€“PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. Clinical Cancer Research, 2019, 25, 946-956.	3.2	96
87	Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nature Reviews Clinical Oncology, 2010, 7, 367-380.	12.5	94
88	VEGF-A Expression Correlates with TP53 Mutations in Nonâ€“Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy. Cancer Research, 2015, 75, 1187-1190.	0.4	92
89	Lung cancer mortality risk among breast cancer patients treated with antiâ€estrogens. Cancer, 2011, 117, 1288-1295.	2.0	90
90	Immune Checkpoint Modulation for Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2015, 21, 2256-2262.	3.2	90

#	Article	IF	Citations
91	MutS Homologue 2 and the Long-term Benefit of Adjuvant Chemotherapy in Lung Cancer. Clinical Cancer Research, 2010, 16, 1206-1215.	3.2	89
92	Challenges in lung cancer therapy during the COVID-19 pandemic. Lancet Respiratory Medicine,the, 2020, 8, 542-544.	5.2	88
93	Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. ESMO Open, 2017, 2, e000219.	2.0	87
94	Telomeres and telomerase as targets for anticancer drug development. Critical Reviews in Oncology/Hematology, 2006, 57, 191-214.	2.0	85
95	Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. PLoS ONE, 2017, 12, e0188174.	1.1	85
96	Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC. Journal of Thoracic Oncology, 2014, 9, 144-153.	0.5	83
97	Tumour molecular profiling for deciding therapyâ€"the French initiative. Nature Reviews Clinical Oncology, 2012, 9, 479-486.	12.5	81
98	ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Current Opinion in Pulmonary Medicine, 2007, 13, 284-289.	1.2	79
99	Are RAS mutations predictive markers of resistance to standard chemotherapy?. Nature Reviews Clinical Oncology, 2009, 6, 528-534.	12.5	79
100	Prognostic and Predictive Effect of TP53 Mutations inÂPatients with Nonâ€"Small Cell Lung Cancer from Adjuvant Cisplatinâ€"Based Therapy Randomized Trials:ÂA LACE-Bio Pooled Analysis. Journal of Thoracic Oncology, 2016, 11, 850-861.	0.5	78
101	Immunotherapy for the First-Line Treatment of Patients with Metastatic Nonâ€"Small Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 2691-2698.	3.2	78
102	Telomere length, telomeric proteins and genomic instability during the multistep carcinogenic process. Critical Reviews in Oncology/Hematology, 2008, 66, 99-117.	2.0	77
103	Aquaporin expression in human lymphocytes and dendritic cells. American Journal of Hematology, 2004, 75, 128-133.	2.0	76
104	Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2011, 29, 3783-3790.	0.8	76
105	Discrepancies between primary tumor and metastasis: A literature review on clinically established biomarkers. Critical Reviews in Oncology/Hematology, 2012, 84, 301-313.	2.0	76
106	Circulating T-cell Immunosenescence in Patients with Advanced Nonâ€"small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. Clinical Cancer Research, 2021, 27, 492-503.	3.2	76
107	Multidrug Resistance Proteins Do Not Predict Benefit of Adjuvant Chemotherapy in Patients with Completely Resected Nonâ€"Small Cell Lung Cancer: International Adjuvant Lung Cancer Trial Biologic Program. Clinical Cancer Research, 2007, 13, 3892-3898.	3.2	73
108	Molecular Screening for a Personalized Treatment Approach in Advanced Adrenocortical Cancer. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4080-4088.	1.8	72

#	Article	IF	Citations
109	Update to Rociletinib Data with the RECIST Confirmed Response Rate. New England Journal of Medicine, 2016, 374, 2296-2297.	13.9	72
110	Tumor Growth Rate Provides Useful Information to Evaluate Sorafenib and Everolimus Treatment in Metastatic Renal Cell Carcinoma Patients: An Integrated Analysis of the TARGET and RECORD Phase 3 Trial Data. European Urology, 2014, 65, 713-720.	0.9	71
111	Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. Investigational New Drugs, 2020, 38, 831-843.	1.2	71
112	Telomerase expression in lung preneoplasia and neoplasia. International Journal of Cancer, 2007, 120, 1835-1841.	2.3	70
113	A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Research and Treatment, 2013, 141, 437-446.	1.1	70
114	Telomere-driven genomic instability in cancer cells. Cancer Letters, 2003, 194, 173-182.	3.2	69
115	NK Cells Infiltrating a MHC Class I-Deficient Lung Adenocarcinoma Display Impaired Cytotoxic Activity toward Autologous Tumor Cells Associated with Altered NK Cell-Triggering Receptors. Journal of Immunology, 2005, 175, 5790-5798.	0.4	69
116	Patient Selection for Oncology Phase I Trials: A Multi-Institutional Study of Prognostic Factors. Journal of Clinical Oncology, 2012, 30, 996-1004.	0.8	68
117	A Comparative and Integrative Approach Identifies ATPase Family, AAA Domain Containing 2 as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma. Clinical Cancer Research, 2012, 18, 5606-5616.	3.2	68
118	Customized Adjuvant Phase II Trial in Patients With Nonâ€“Small-Cell Lung Cancer: IFCT-0801 TASTE. Journal of Clinical Oncology, 2014, 32, 1256-1261.	0.8	66
119	PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer. Cancer Research, 2021, 81, 2888-2902.	0.4	66
120	Biology-Driven Phase II Trials: What Is the Optimal Model for Molecular Selection?. Journal of Clinical Oncology, 2011, 29, 1236-1238.	0.8	65
121	Circulating Tumor Cells in Lung Cancer. Acta Cytologica, 2012, 56, 655-660.	0.7	65
122	Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Nonâ€“Small Cell Lung Cancer Patients. Cancer Research, 2017, 77, 2222-2230.	0.4	64
123	TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. ESMO Open, 2018, 3, e000257.	2.0	62
124	Phase I, Dose-Finding, and Pharmacokinetic Study of Raltitrexed Combined With Oxaliplatin in Patients With Advanced Cancer. Journal of Clinical Oncology, 2000, 18, 2293-2300.	0.8	61
125	A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours. British Journal of Cancer, 2019, 120, 975-981.	2.9	61
126	Association of a functional tandem repeats in the downstream of human telomerase gene and lung cancer. Oncogene, 2003, 22, 7123-7129.	2.6	60

#	Article	IF	Citations
127	Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RASâ€“RAF Mutations. Clinical Cancer Research, 2014, 20, 4251-4261.	3.2	60
128	ERCC1 and RRM1 in the International Adjuvant Lung Trial by Automated Quantitative in Situ Analysis. American Journal of Pathology, 2011, 178, 69-78.	1.9	59
129	Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition. Cancer Treatment Reviews, 2017, 55, 83-95.	3.4	58
130	Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. Cell Cycle, 2013, 12, 877-883.	1.3	57
131	Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC. Clinical Cancer Research, 2011, 17, 5562-5572.	3.2	56
132	hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer. Clinical Cancer Research, 2002, 8, 2883-9.	3.2	56
133	Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma. JAMA Oncology, 2018, 4, 1189.	3.4	53
134	Chemoprevention of lung cancer. Lancet Oncology, The, 2003, 4, 659-669.	5.1	52
135	Differential Expression of Biomarkers in Men and Women. Seminars in Oncology, 2009, 36, 553-565.	0.8	52
136	Implications of personalized medicineâ€”perspective from a cancer center. Nature Reviews Clinical Oncology, 2011, 8, 177-183.	12.5	52
137	IFCT-0401 Trial: A Phase II Study of Gefitinib Administered as First-Line Treatment in Advanced Adenocarcinoma with Bronchioloalveolar Carcinoma Subtype. Journal of Thoracic Oncology, 2009, 4, 1126-1135.	0.5	51
138	Personalized treatments of cancer patients: A reality in daily practice, a costly dream or a shared vision of the future from the oncology community?. Cancer Treatment Reviews, 2014, 40, 1192-1198.	3.4	51
139	Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast. Anticancer Research, 2007, 27, 547-55.	0.5	51
140	Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors. Clinical Cancer Research, 2017, 23, 2423-2432.	3.2	50
141	Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells. Cancer Discovery, 2012, 2, 434-449.	7.7	49
142	Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib) Tj ETQq0 0 0 rgBT /Overlock 10 T New Drugs, 2010, 28, 199-202.	1.2	48
143	A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors. Cell Cycle, 2011, 10, 963-970.	1.3	48
144	Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review. Cancer and Metastasis Reviews, 2013, 32, 479-492.	2.7	46

#	Article	IF	Citations
145	Novel therapeutic targets in advanced urothelial carcinoma. Critical Reviews in Oncology/Hematology, 2016, 98, 106-115.	2.0	45
146	Human telomerase reverse transcriptase (hTERT) and Ki-67 are better predictors of survival than established clinical indicators in patients undergoing curative hepatic resection for colorectal metastases. Annals of Surgical Oncology, 2004, 11, 45-51.	0.7	44
147	Dependence on Phosphoinositide 3-Kinase and RAS-RAF Pathways Drive the Activity of RAF265, a Novel RAF/VEGFR2 Inhibitor, and RAD001 (Everolimus) in Combination. Molecular Cancer Therapeutics, 2010, 9, 358-368.	1.9	44
148	Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars. JCO Global Oncology, 2020, 6, 1461-1471.	0.8	44
149	Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2013, 19, 4832-4842.	3.2	43
150	Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies. Clinical Cancer Research, 2017, 23, 6411-6420.	3.2	43
151	A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2020, 26, 1229-1236.	3.2	43
152	A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Nonâ€“Small Cell Lung Cancer Based on Early Tumor Kinetics. Clinical Cancer Research, 2018, 24, 3292-3298.	3.2	41
153	Bioluminescent Orthotopic Mouse Models of Human Localized Non-Small Cell Lung Cancer: Feasibility and Identification of Circulating Tumour Cells. PLoS ONE, 2011, 6, e26073.	1.1	41
154	Quantitative Proteomics Profiling of Primary Lung Adenocarcinoma Tumors Reveals Functional Perturbations in Tumor Metabolism. Journal of Proteome Research, 2013, 12, 3934-3943.	1.8	40
155	Translating metastasis-related biomarkers to the clinicâ€”progress and pitfalls. Nature Reviews Clinical Oncology, 2013, 10, 169-179.	12.5	40
156	IGF-1R Targeting Increases the Antitumor Effects of DNA-Damaging Agents in SCLC Model: An Opportunity to Increase the Efficacy of Standard Therapy. Molecular Cancer Therapeutics, 2013, 12, 1213-1222.	1.9	40
157	DNA Damage Repair and Telomere Length in Normal Breast, Preneoplastic Lesions, and Invasive Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 341-345.	0.6	39
158	Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 369-375.	0.5	38
159	Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: A review of published data. Critical Reviews in Oncology/Hematology, 2010, 75, 94-109.	2.0	38
160	The Role of Antiâ€“Epidermal Growth Factor Receptor and Antiâ€“Vascular Endothelial Growth Factor Therapies in the Treatment of Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2010, 11, 82-90.	1.1	38
161	Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials. Investigational New Drugs, 2012, 30, 611-615.	1.2	38
162	Different Expression Levels of the TAP Peptide Transporter Lead to Recognition of Different Antigenic Peptides by Tumor-Specific CTL. Journal of Immunology, 2011, 187, 5532-5539.	0.4	37

#	Article	IF	Citations
163	Vascular disrupting agents. Current Opinion in Oncology, 2012, 24, 305-315.	1.1	37
164	ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform. Cell Cycle, 2013, 12, 3298-3306.	1.3	37
165	Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients. Blood, 2015, 126, 473-473.	0.6	37
166	Erythropoietin and Erythropoietin Receptor Coexpression Is Associated with Poor Survival in Stage I Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 4825-4831.	3.2	36
167	Loss-of-function alleles ofP2RX7andTLR4fail to affect the response to chemotherapy in non-small cell lung cancer. OncoImmunology, 2012, 1, 271-278.	2.1	36
168	Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients. Clinical Cancer Research, 2014, 20, 265-272.	3.2	36
169	Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1594-1601.	0.5	35
170	Telomere Maintenance and DNA Damage Responses during Lung Carcinogenesis. Clinical Cancer Research, 2010, 16, 2979-2988.	3.2	34
171	Impact of Bioinformatic Procedures in the Development and Translation of High-Throughput Molecular Classifiers in Oncology. Clinical Cancer Research, 2013, 19, 4315-4325.	3.2	32
172	Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147), a Pan-Class I PI3K Inhibitor, in Combination With Erlotinib in Patients With Solid Tumors. Oncologist, 2015, 20, 245-246.	1.9	32
173	Lung Cancer Stem Cell: Fancy Conceptual Model of Tumor Biology or Cornerstone of a Forthcoming Therapeutic Breakthrough?. Journal of Thoracic Oncology, 2014, 9, 7-17.	0.5	31
174	Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC. Journal of Thoracic Oncology, 2016, 11, 1819-1836.	0.5	31
175	Phase 1 study of the immunotoxin LMBâ€100 in patients with mesothelioma and other solid tumors expressing mesothelin. Cancer, 2020, 126, 4936-4947.	2.0	31
176	Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. Cell Death and Differentiation, 2021, 28, 3297-3315.	5.0	31
177	QT interval prolongation among patients treated with angiogenesis inhibitors. Targeted Oncology, 2009, 4, 89-97.	1.7	30
178	Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer. Clinical Cancer Research, 2003, 9, 1785-91.	3.2	30
179	Phase I clinical trial combining imatinib mesylate and IL-2. OncoImmunology, 2013, 2, e23080.	2.1	29
180	LDK378 Compassionate Use for Treating Carcinomatous Meningitis in an ALK Translocated Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2014, 9, e62-e63.	0.5	29

#	Article	IF	Citations
181	DNA G-quadruplexes, telomere-specific proteins and telomere-associated enzymes as potential targets for new anticancer drugs. Investigational New Drugs, 2000, 18, 123-137.	1.2	28
182	Gene expression profiling of non-small-cell lung cancer. Expert Review of Molecular Diagnostics, 2008, 8, 167-178.	1.5	28
183	A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis. Leukemia Research, 2015, 39, 157-163.	0.4	28
184	PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. Cancer Discovery, 2022, 12, 1435-1448.	7.7	28
185	Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway. International Immunology, 2008, 20, 801-810.	1.8	27
186	Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF -Mutated Lung Adenocarcinoma. Journal of Thoracic Oncology, 2016, 11, e109-e112.	0.5	27
187	An Accessible and Unique Insight into Metastasis Mutational Content Through Whole-exome Sequencing of Circulating Tumor Cells in Metastatic Prostate Cancer. European Urology Oncology, 2020, 3, 498-508.	2.6	27
188	Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma. Journal of Clinical Investigation, 2019, 130, 612-624.	3.9	27
189	Nuclear Localization of Apoptosis Protease Activating Factor-1 Predicts Survival after Tumor Resection in Early-Stage Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 5665-5669.	3.2	26
190	Immune checkpoint inhibitors in advanced nonsmall cell lung cancer. Current Opinion in Oncology, 2015, 27, 108-117.	1.1	26
191	Inhibition of the NKp44-PCNA Immune Checkpoint Using a mAb to PCNA. Cancer Immunology Research, 2019, 7, 1120-1134.	1.6	26
192	Interventional Radiology for Local Immunotherapy in Oncology. Clinical Cancer Research, 2021, 27, 2698-2705.	3.2	26
193	The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer. Expert Review of Molecular Diagnostics, 2015, 15, 1605-1629.	1.5	25
194	Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology, 2017, 79, 1257-1265.	1.1	25
195	Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. British Journal of Cancer, 2017, 116, 1505-1512.	2.9	25
196	Maintenance Therapy and Advanced Nonâ€“Small-Cell Lung Cancer: A Skeptic's View. Journal of Thoracic Oncology, 2012, 7, 1331-1336.	0.5	24
197	JAK Mutations as Escape Mechanisms to Antiâ€“PD-1 Therapy. Cancer Discovery, 2017, 7, 128-130.	7.7	24
198	The cost of molecular-guided therapy in oncology: a prospective cost study alongside the MOSCATO trial. Genetics in Medicine, 2017, 19, 683-690.	1.1	24

#	Article	IF	Citations
199	Translational regulation of the mRNA encoding the ubiquitin peptidase USP1 involved in the DNA damage response as a determinant of Cisplatin resistance. Cell Cycle, 2016, 15, 295-302.	1.3	23
200	A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors. Clinical Cancer Research, 2017, 23, 1177-1185.	3.2	23
201	Methodological Development of Combination Drug and Radiotherapy in Basic and Clinical Research. Clinical Cancer Research, 2020, 26, 4723-4736.	3.2	23
202	Mechanisms of Disease: signal transduction in lung carcinogenesisâ€"a comparison of smokers and never-smokers. Nature Clinical Practice Oncology, 2008, 5, 610-618.	4.3	22
203	p38 mitogenâ€activated protein kinase signaling, ERCC1 expression, and viability of lung cancer cells from never or light smoker patients. Cancer, 2012, 118, 5015-5025.	2.0	22
204	A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma. Investigational New Drugs, 2013, 31, 1530-1538.	1.2	22
205	A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib. Investigational New Drugs, 2016, 34, 397-398.	1.2	22
206	Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3. Oncotarget, 2017, 8, 108786-108801.	0.8	22
207	A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget, 2015, 6, 14139-14152.	0.8	22
208	Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types. Cancer Medicine, 2020, 9, 2643-2652.	1.3	21
209	Retinoic Acid Receptor Â and Telomerase Catalytic Subunit Expression in Bronchial Epithelium of Heavy Smokers. Journal of the National Cancer Institute, 2003, 95, 165-168.	3.0	20
210	Mitogen-Activated Protein Kinase Activation in Lung Adenocarcinoma: A Comparative Study between Ever Smokers and Never Smokers. Clinical Cancer Research, 2008, 14, 4096-4102.	3.2	20
211	Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors. Investigational New Drugs, 2014, 32, 1188-1196.	1.2	20
212	Patient-reported tolerability of adverse events in phase 1 trials. ESMO Open, 2017, 2, e000148.	2.0	20
213	Osimertinib inEGFRMutationâ€"Positive Advanced NSCLC. New England Journal of Medicine, 2018, 378, 1261-1263.	13.9	20
214	Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19. Cancer Discovery, 2021, 11, 1336-1344.	7.7	20
215	Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations. International Journal of Cancer, 2006, 118, 1068-1069.	2.3	19
216	Validation of ERCC1-XPF Immunodetection â€" Letter. Cancer Research, 2010, 70, 3851-3852.	0.4	19

#	Article	IF	Citations
217	Minimal residual disease in solid neoplasia: New frontier or red-herring?. Cancer Treatment Reviews, 2012, 38, 101-110.	3.4	19
218	Dysphonia induced by anti-angiogenic compounds. Investigational New Drugs, 2014, 32, 774-782.	1.2	19
219	Mutation of TP53 and Alteration of p14arf Expression in EGFR- and KRAS-Mutated Lung Adenocarcinomas. Clinical Lung Cancer, 2014, 15, 124-130.	1.1	19
220	DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade. Journal of Clinical Investigation, 2018, 128, 1671-1687.	3.9	19
221	Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2008, 3, 677-679.	0.5	18
222	Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2011, 68, 53-61.	1.1	18
223	Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients. OncoImmunology, 2013, 2, e23079.	2.1	18
224	Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours. British Journal of Cancer, 2015, 113, 1413-1420.	2.9	18
225	P2.39: Long-Term OS for Patients WithÂAdvanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab. Journal of Thoracic Oncology, 2016, 11, S241-S242.	0.5	18
226	Europe Does It Better: Molecular Testing across a National Health Care Systemâ€"The French Example. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, 332-337.	1.8	18
227	Dysphonia induced by vascular endothelium growth factor/vascular endothelium growth factor receptor inhibitors. Investigational New Drugs, 2010, 28, 884-886.	1.2	17
228	Implementing precision medicine initiatives in the clinic. Current Opinion in Oncology, 2014, 26, 340-346.	1.1	17
229	Pharmacokinetics of pazopanib administered in combination with bevacizumab. Cancer Chemotherapy and Pharmacology, 2014, 73, 1189-1196.	1.1	17
230	Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors. Cancer Journal (Sudbury, Mass), 2018, 24, 153-162.	1.0	17
231	Reply to A.H. Fischer et al. Journal of Clinical Oncology, 2011, 29, 3332-3333.	0.8	16
232	Prognostic value of LIPC in non-small cell lung carcinoma. Cell Cycle, 2013, 12, 647-654.	1.3	16
233	Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survival. Journal of Neuro-Oncology, 2015, 123, 307-314.	1.4	16
234	Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations. Cancer Research, 2016, 76, 5954-5961.	0.4	16

#	Article	IF	Citations
235	First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma. Cancer Chemotherapy and Pharmacology, 2019, 83, 1057-1063.	1.1	16
236	Inhibition of BCL-2 in small cell lung cancer cell lines with oblimersen, an antisense BCL-2 oligodeoxynucleotide (ODN): in vitro and in vivo enhancement of radiation response. Anticancer Research, 2010, 30, 3869-78.	0.5	16
237	Use of Adjuvant Chemotherapy in Non-small Cell Lung Cancer in Routine Practice. Journal of Thoracic Oncology, 2009, 4, 1504-1510.	0.5	15
238	Transcriptional Analysis of an E2F Gene Signature as a Biomarker of Activity of the Cyclin-Dependent Kinase Inhibitor PHA-793887 in Tumor and Skin Biopsies from a Phase I Clinical Study. Molecular Cancer Therapeutics, 2010, 9, 1265-1273.	1.9	15
239	Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients. Oncotarget, 2016, 7, 25549-25557.	0.8	15
240	Breast metastasis from lung adenocarcinoma: a case report. Anticancer Research, 2003, 23, 1825-6.	0.5	15
241	Molecular Detection of Early-Stage Laryngopharyngeal Squamous Cell Carcinomas. Clinical Cancer Research, 2005, 11, 2547-2551.	3.2	14
242	Pemetrexed-Induced Pneumonitis: A Case Report. Clinical Lung Cancer, 2009, 10, 364-366.	1.1	14
243	PARP Inhibitors: An Interesting Pathway also for Non-Small Cell Lung Cancer?. Current Pharmaceutical Design, 2014, 20, 3875-3882.	0.9	14
244	Dose-Levels and First Signs of Efficacy in Contemporary Oncology Phase 1 Clinical Trials. PLoS ONE, 2011, 6, e16633.	1.1	13
245	Loss of PTEN expression is not uncommon, but lacks prognostic value in stage I NSCLC. Anticancer Research, 2003, 23, 4885-90.	0.5	13
246	Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer. Future Oncology, 2014, 10, 823-833.	1.1	12
247	Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma. Cancer Biomarkers, 2015, 15, 151-156.	0.8	12
248	An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1) Tj ETQq0 0 0 rgBT /Overlock 1 tumors. Anti-Cancer Drugs, 2016, 27, 342-348.	0.7	12
249	Early clinical efficacy of TAS-120, a covalently bound FGFR inhibitor, in patients with cholangiocarcinoma. Annals of Oncology, 2017, 28, iii145.	0.6	12
250	Patterns of progression in patients treated for immuno-oncology antibodies combination. Cancer Immunology, Immunotherapy, 2021, 70, 221-232.	2.0	12
251	Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. Oncotarget, 2018, 9, 9741-9750.	0.8	12
252	Response to Erlotinib in First-Line Treatment of Nonâ€“Small-Cell Lung Cancer in a White Male Smoker with Squamous-Cell Histology. Clinical Lung Cancer, 2006, 8, 214-216.	1.1	11

#	Article	IF	Citations
253	10-year long-term survival of a metastaticEGFR-mutated nonsmall cell lung cancer patient. European Respiratory Journal, 2015, 46, 280-282.	3.1	11
254	Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer. Translational Lung Cancer Research, 2018, 7, 416-427.	1.3	11
255	Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase InhibitorsÂinÂPatients With NSCLC: A Brief Report. JTO Clinical and Research Reports, 2020, 1, 100023.	0.6	11
256	SARS-CoV-2 vaccination and phase 1 cancer clinical trials. Lancet Oncology, The, 2021, 22, 298-301.	5.1	11
257	Adjuvant Chemotherapy in Early-Stage Non-Small Cell Lung Cancer. Seminars in Oncology, 2005, 32, 279-283.	0.8	10
258	An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpes viridae. Cell Cycle, 2011, 10, 118-126.	1.3	10
259	Genomes in the clinic: the Gustave Roussy Cancer Center experience. Current Opinion in Genetics and Development, 2014, 24, 99-106.	1.5	10
260	A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials. PLoS ONE, 2016, 11, e0154895.	1.1	10
261	Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas. Anti-Cancer Drugs, 2017, 28, 341-349.	0.7	10
262	Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial. JTO Clinical and Research Reports, 2020, 1, 100068.	0.6	10
263	Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer. Investigational New Drugs, 2021, 39, 193-201.	1.2	10
264	Telomerase Activity in Cancer. Advances in Anatomic Pathology, 1998, 5, 86-94.	2.4	9
265	Expression of Cell Cycle Biomarkers and Telomere Length in Papillary Thyroid Carcinoma: A Comparative Study Between Radiation-Associated and Spontaneous Cancers. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 1-8.	0.6	9
266	Chemotherapy Effectiveness After First-Line Gefitinib Treatment for Advanced Lepidic Predominant Adenocarcinoma (Formerly Advanced Bronchioloalveolar Carcinoma): Exploratory Analysis of the IFCT-0401 Trial. Journal of Thoracic Oncology, 2012, 7, 1423-1431.	0.5	9
267	19q13-ERCC1 Gene Copy Number Increase in Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2013, 14, 549-557.	1.1	9
268	Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor. Journal of Thoracic Oncology, 2016, 11, e21-e23.	0.5	8
269	A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors. Oncotarget, 2017, 8, 56199-56209.	0.8	8
270	Adjuvant chemotherapy and radiotherapy in non-small cell lung cancer. Seminars in Radiation Oncology, 2004, 14, 315-321.	1.0	7

#	Article	IF	Citations
271	QTc Monitoring During a Phase I Study. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 106-112.	0.6	7
272	D3-03: IALT-Bio: a challenging research to improve adjuvant chemotherapy of completely resected NSCLC. Journal of Thoracic Oncology, 2007, 2, S397-S398.	0.5	7
273	Inclusion of Patients With Advanced Cancer in Phase I Trials: Is This a Tool for Improving Optimism and Emotional Well-Being?. Journal of Clinical Oncology, 2013, 31, 817-818.	0.8	7
274	MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer. Cancer Biomarkers, 2016, 17, 323-333.	0.8	7
275	Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors. Anti-Cancer Drugs, 2016, 27, 1021-1027.	0.7	7
276	A novel antibody-based approach to detect the functional ERCC1-202 isoform. DNA Repair, 2018, 64, 34-44.	1.3	7
277	Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. British Journal of Cancer, 2018, 118, 344-352.	2.9	7
278	Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1â€“Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. Obstetrical and Gynecological Survey, 2018, 73, 26-27.	0.2	7
279	Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors. Investigational New Drugs, 2018, 36, 619-628.	1.2	7
280	Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?. British Journal of Cancer, 2018, 119, 937-939.	2.9	7
281	Concomitant chemo-radiotherapy in clinical trials: To promote step by step rational development. Critical Reviews in Oncology/Hematology, 2009, 70, 206-215.	2.0	6
282	Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials. Investigational New Drugs, 2012, 30, 1116-1120.	1.2	6
283	Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples. Investigational New Drugs, 2014, 32, 312-322.	1.2	6
284	MA08.01 A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma. Journal of Thoracic Oncology, 2017, 12, S384-S385.	0.5	6
285	Wound healing delay after central venous access following DCF/VEGF-trap therapy. Investigational New Drugs, 2009, 27, 583-585.	1.2	5
286	Trastuzumab-Induced Cardiotoxicity. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 183-184.	0.6	5
287	Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Nonâ€“Small Cell Lung Cancer Patient. Journal of Thoracic Oncology, 2015, 10, e72-e73.	0.5	5
288	First Reported Case of Unexpected Response to an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the I744M Uncommon EGFR Mutation. Clinical Lung Cancer, 2015, 16, e259-e261.	1.1	5

#	Article	IF	Citations
289	Patients aged over 75 years enrolled in Phase I clinical trials: the <scp>G</scp>ustave <scp>R</scp>oussy experience. International Journal of Cancer, 2016, 138, 875-880.	2.3	5
290	Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients. Translational Lung Cancer Research, 2021, 10, 826-838.	1.3	5
291	Natural Language Processing for Patient Selection in Phase I or II Oncology Clinical Trials. JCO Clinical Cancer Informatics, 2021, 5, 709-718.	1.0	5
292	Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors. Chinese Clinical Oncology, 2015, 4, 48.	0.4	5
293	Mutations in JAK2^{V617F} homologous domain of JAK genes are uncommon in solid tumors. International Journal of Cancer, 2007, 121, 2113-2115.	2.3	4
294	Brain Radionecrosis Treated with Bevacizumab in a Patient with Resected Squamous Cell Carcinoma ofÂthe Lung. Journal of Thoracic Oncology, 2017, 12, e1-e3.	0.5	4
295	Are phase I trials safe for older patients?. Journal of Geriatric Oncology, 2018, 9, 87-92.	0.5	4
296	Comprehensive Genome Profiling in Patients With Metastatic Nonâ€“Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial. Clinical Cancer Research, 2022, 28, 4018-4026.	3.2	4
297	Reversible cardiogenic shock following 5-Fluorouracil infusion. Investigational New Drugs, 2010, 28, 531-533.	1.2	3
298	TGR Analysis in Phase I Clinical Trialsâ€”Response. Clinical Cancer Research, 2014, 20, 2497-2497.	3.2	3
299	PS01.62: Long-Term Safety and Clinical ActivityÂof Atezolizumab MonotherapyÂin Metastatic NSCLC: FinalÂResults from a Phase Ia Study. Journal of Thoracic Oncology, 2016, 11, S309-S310.	0.5	3
300	P3.02b-102 Osimertinib Benefit in ctDNA T790M Positive, EGFR-Mutant NSCLC Patients. Journal of Thoracic Oncology, 2017, 12, S1254-S1255.	0.5	3
301	Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials. Investigational New Drugs, 2017, 35, 79-86.	1.2	3
302	Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials. Investigational New Drugs, 2018, 36, 62-74.	1.2	3
303	P3.02a-025 PROs With Ceritinib Versus Chemotherapy in Patients With Previously Untreated ALK-rearranged Nonsquamous NSCLC (ASCEND-4). Journal of Thoracic Oncology, 2017, 12, S1176-S1177.	0.5	2
304	The â€œGuardian of the Genomeâ€â€”An Old Key to Unlock the ERCC1 Issue. Clinical Cancer Research, 2019, 25, 2369-2371.	3.2	2
305	Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large <scp>B</scp>â€cell lymphoma: Results of <scp>LNHâ€EP1</scp> study. American Journal of Hematology, 2021, 96, E376-E379.	2.0	2
306	Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic. Cancer Cell, 2021, 39, 1039-1041.	7.7	2

#	Article	IF	Citations
307	Late phase 1 studies: concepts and outcomes. Lancet Oncology, The, 2021, 22, e446-e455.	5.1	2
308	P3-071: Respiratory symptoms improvement in non-resectable adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC) treated with gefitinib: Quality of Life analysis of the IFCT-0401 trial. Journal of Thoracic Oncology, 2007, 2, S708.	0.5	1
309	Proteinuria and proximal tubule lesions induced by an anti-integrin monoclonal antibody treatment: case report. Investigational New Drugs, 2010, 28, 102-105.	1.2	1
310	Acute left ventricular dysfunction induced by a panHER and VEGFR tyrosine kinase inhibitor in a phase I trial. Investigational New Drugs, 2010, 28, 350-352.	1.2	1
311	What can be done for patients with NSCLC without druggable targets?. Lancet Oncology, The, 2013, 14, 191-192.	5.1	1
312	P3.02b-003 Second-Line Afatinib versus Erlotinib for Patients with Squamous Cell Carcinoma of the Lung (LUX-Lung 8): Analysis of Tumor and Serum Biomarkers. Journal of Thoracic Oncology, 2017, 12, S1186-S1187.	0.5	1
313	Otorhinolaryngological Toxicities of New Drugs in Oncology. Advances in Therapy, 2017, 34, 866-894.	1.3	1
314	Prognostic factors and outcome of patients with hematological malignancies in phase I trials. Anti-Cancer Drugs, 2017, 28, 540-545.	0.7	1
315	Advanced non-small-cell lung cancer: 'triplets' better than 'doublets'?. Nature Clinical Practice Oncology, 2006, 3, 476-477.	4.3	0
316	Nonapoptotic Role for Apaf-1 in the DNA Damage Checkpoint. Molecular Cell, 2012, 48, 322-324.	4.5	0
317	LUX-Lung 8: A Global Phase III Trial of Afatinib (A) vs Erlotinib (E) as Second-Line Treatment in Patients (Pts) With Advanced Squamous Cell Carcinoma (SCC) of the Lung Following First-Line Platinum-Based Chemotherapy. Chest, 2015, 148, 585A.	0.4	0
318	Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials. International Journal of Cardiology, 2016, 214, 364-369.	0.8	0
319	Liquid biopsies could be superior to tumor biopsy to provide a molecular profile in non-small cell lung cancer (NSCLC) patients. Journal of Thoracic Oncology, 2016, 11, S37.	0.5	0
320	SC05.02 Novel Cytotoxic Drugs in Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S85-S86.	0.5	0
321	P2.03b-050 Prognostic Value of HLA-A2 Status in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients. Journal of Thoracic Oncology, 2017, 12, S965-S966.	0.5	0
322	P3.02c-031 Immune Checkpoint Inhibitors (IC) and Paradoxical Progressive Disease (PPD) in a Subset of Non-Small Cell Lung Cancer (NSCLC) Patients. Journal of Thoracic Oncology, 2017, 12, S1291-S1292.	0.5	0
323	OA06.05 Proteomic Analysis of ERCC1 Predicts Benefit of Platinum Therapy in NSCLC: AÂReevaluation of Samples from the TASTE Trial. Journal of Thoracic Oncology, 2017, 12, S265-S266.	0.5	0
324	JosÃ© â€œPepeâ€•Baselga, MD, PhD: In Memoriam (1959â€“2021). Cancer Discovery, 2021, 11, 1614-1616.	7.7	0

#	Article	IF	Citations
325	A Simple Scoring System for Identifying Relapsed/Refractory Lymphoma Patients Prematurely Withdrawn from Phase I Trials: The Gustave Roussy Experience. Blood, 2014, 124, 1759-1759.	0.6	0
326	Prognostic Factors and Outcome of Patients with Hematological Malignancies in Phase I Trials: The Gustave Roussy Scoring System. Blood, 2014, 124, 3504-3504.	0.6	0
327	Feasibility and Benefit of Molecularly-Informed Enrollment into Personalized Therapies or Early Phase Trials for Patients with Relapsed or Refractory Multiple Myeloma. Blood, 2018, 132, 2001-2001.	0.6	0
328	Feasibility and Benefit of Molecularly-Informed Enrollment into Early Phase Clinical Trials for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Blood, 2018, 132, 4110-4110.	0.6	0
329	MET Receptor Amplification Drives Resistance to Anti-EGFR Therapies. Journal of Immunotherapy and Precision Oncology, 2019, 2, 152-155.	0.6	0